Metformin HCL ER
ID: SPE2D2-23-D-0008Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f29923ee78c24d5ca99ae10b5174bcc6/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.

    Files
    Title
    Posted
    Metformin Award SPE2D223D0008 Final BILATERLLY signed.pdf
    Lifecycle
    Title
    Type
    Metformin HCL ER
    Currently viewing
    Special Notice
    Similar Opportunities
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    6505--Metformin SA Tablets REPACK PROGRAM
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Metformin HCL SA Tablets, aimed at ensuring a consistent supply for various governmental entities, including the VA, Department of Defense, Bureau of Prisons, and others. The procurement will cover a one-year contract with the possibility of four additional one-year extensions, requiring offerors to provide a unique National Drug Code (NDC) number and distinct labeling for the supplied products. This initiative is critical for maintaining the availability of essential pharmaceuticals, with estimated annual requirements detailed for two groups: Other Government Agencies and the VA Repack Program. The solicitation, numbered 36E79725R0003, is scheduled for electronic release on December 3, 2024, with a closing date of December 17, 2024. Interested parties can direct inquiries to Teresa Hussain at teresa.hussain@va.gov or by phone at 708-786-5852, and are encouraged to monitor SAM.gov for updates.
    Lamotrigine
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.
    Tolterodine Tartrate ER
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is seeking Tolterodine Tartrate ER. Tolterodine Tartrate ER is a drug used for the treatment of overactive bladder. The procurement will be fulfilled by DLA Troop Support in Philadelphia, PA, USA. For more information, contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Pramipexole Tablets
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Pramipexole Tablets under solicitation number SPE2D2-24-R-0017. This procurement aims to acquire pharmaceutical products, specifically Pramipexole in various dosages, to support military health needs. The solicitation outlines detailed requirements for offerors, including submission instructions via the Defense Logistics Agency Internet Bid Board System (DIBBS), compliance with federal regulations, and the necessity for performance assessments and ethical conduct. Interested contractors should reach out to Ryan Guarnere at Ryan.Guarnere@dla.mil or Jason Wray at jason.wray@dla.mil for further information regarding the submission process and compliance requirements.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a presolicitation for a national requirements contract for Norgestimate/Ethinyl Estradiol Tablets. The procurement will include various formulations of these oral tablets, specifically Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and Ethinyl Estradiol/Norgestimate tablets, packaged in 3x28 count packs. This contract is crucial for establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable provision of these essential pharmaceuticals. Interested parties should prepare for the solicitation, projected for November 2024, and may contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for further inquiries.
    Duloxetine HCL DR
    Active
    Dept Of Defense
    Presolicitation notice for Duloxetine HCL DR. The service/item being procured is typically used for medical, dental, and veterinary equipment and supplies. The place of performance is in Philadelphia, PA, USA at DLA Troop Support, 700 Robbins Avenue, 19111. The primary contact for this procurement is Joan Grace, who can be reached at JoanMarie.Grace@dla.mil or 215-737-2663.
    Trazodone HCL
    Active
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is procuring Trazodone HCL, a drug used for treating depression and anxiety. The procurement will take place at DLA Troop Support in Philadelphia, PA (zip code: 19111), USA. For more information, contact Christopher Newman at christopher.newman@dla.mil or 215-737-2905.